Vizex Investments Ltd
financial consultations

Last news

Transenterix announces 1st US sale

Nov 13, 2017 14
November 13th. Transenterix Inc…

We no longer recommend Array Biopharma Inc

Nov 11, 2017 10
November 11th 2017. We are withdrawing…

Transenterix Director purchases 40 000 shares

August 24 2016 Transenterix Director Andrea Biffi purchased 40 000 shares of the company at the average price of $1.4 on Monday August 22.  Shares of Transenterix went up 13% after the news and closed at $1.62 on Tuesday.

Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress

August 19th, 2016.   Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 – 31, 2016 in Rome, Italy.   Presentation will be held at 10.19 CEST on August 30th.  

 

Phase 2 has shown that treatment with A797 was well tolerated and resulted in meaningful, sustained increases in functional capacity and cardiac function in patients with LMNA-related DCM as measured by changes in 6MWT, NT-proBNP, LVEF and QoL.

Вайзекс Инвестментс ООД © 2015 | Всички права запазени